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DNA polymerase b (pol b) is the only mammalian
DNA polymerase identified to date that can catalyze
extensive bypass of platinum-DNA adducts in vitro.
Previous studies suggest that DNA synthesis by pol b is
distributive on primed single-stranded DNA and pro-
cessive on gapped DNA. The data presented in this
paper provide an analysis of translesion synthesis past
cisplatin- and oxaliplatin-DNA adducts by pol b func-
tioning in both distributive and processive modes us-
ing primer extension and steady-state kinetic experi-
ments. Translesion synthesis past Pt-DNA adducts was
greater with gapped DNA templates than with single-
stranded DNA templates. In the processive mode pol b
did not discriminate between cisplatin and oxaliplatin
adducts, while in the distributive mode it displayed
about 2-fold increased ability for translesion synthesis
past oxaliplatin compared with cisplatin adducts. The
differentiation between cisplatin and oxaliplatin ad-
ducts resulted from a Km-mediated increase in the ef-
ficiency of dCTP incorporation across from the 3*-G of
oxaliplatin-GG adducts. Rates of misincorporation
across platinated guanines determined by the steady-
state kinetic assay were higher in reactions with
primed single-stranded templates than with gapped
DNA and a slight increase in the misincorporation of
dTTP across from the 3*-G was found for oxaliplatin
compared with cisplatin adducts.
Decreased DNA synthesis during replication is responsible
in part for the chemotherapeutic effect of drugs which form
bulky adducts on the DNA. Mammalian cells contain a post-
replication repair pathway that allows cells to overcome repli-
cation blocks caused by these adducts. Post-replication repair
can be either error-free, which would increase cellular toler-
ance of bulky adducts, or error-prone, which would increase the
mutagenicity of bulky adducts. Previous studies have shown
that mammalian cells possess the ability to replicate DNA
containing cisplatin (cis-diamminedichloroplatinum(II))1 ad-
ducts and that cisplatin-resistant cell lines have a greater
ability to replicate past Pt-DNA adducts than their parental
cisplatin-sensitive cell lines (1–4). This suggests that some
cellular DNA polymerases must be able to replicate Pt-contain-
ing DNA relatively well and tolerant cells might have either
elevated levels of the polymerases responsible for lesion bypass
or mutant DNA polymerases with enhanced translesion repli-
cation activity.
DNA polymerase b has been suggested as a candidate for the
role of a DNA polymerase that performs error-prone transle-
sion synthesis of cisplatin-DNA adducts (5, 6). Pol b is the only
mammalian DNA polymerase identified to date that has been
shown to catalyze extensive replicative bypass of Pt-DNA ad-
ducts in vitro (5–8). In addition, pol b is able to elongate the
arrested replication products of polymerases a and d, thus
showing its capacity to successfully complete stalled replication
(5). The full-length DNA products of translesion synthesis by
pol b contain a high frequency of mutations in the vicinity of
the Pt-DNA adducts (6). On the basis of these data, Hoffmann
et al. (5, 6) have suggested that pol b could be involved in
error-prone translesion replication past Pt-DNA adducts in
vivo. In support of this hypothesis, increased cisplatin resist-
ance (9–12) and an increased rate of both spontaneous and
cisplatin-induced mutagenesis (12) have been observed in cell
lines with increased pol b expression. This has lead to the
suggestion that overexpression of pol b could be associated with
cisplatin resistance and a mutator phenotype (12–14). If this
hypothesis is correct it could be significant, since some sponta-
neously occurring tumors appear to overexpress pol b (15), and
pol b gene amplification has been detected in tumors from
patients that have failed cisplatin therapy (9). Although cell
lines expressing pol b antisense RNA show decreased sensitiv-
ity to cisplatin (16), no increased sensitivity to cisplatin has
been seen in pol b-deleted cells (17). Thus, the available data
suggest that pol b overexpression might represent an impor-
tant mechanism of platinum drug resistance and mutagenicity,
but it is not yet clear whether pol b makes a significant con-
tribution to error-prone translesion synthesis at normal levels
of expression.
Although to date there is no direct evidence showing that pol
b actually carries out error-prone DNA synthesis past bulky
DNA adducts in vivo, one can envision at least two models for
its involvement in translesion synthesis during in vivo replica-
tion. 1) Pol b might substitute for a replication complex that
had stalled at Pt-DNA lesion sites during chromosomal repli-
cation. After error-prone translesion synthesis, pol b would
dissociate. Then the replication complex could reassociate at
the nascent primer terminus downstream from the lesion and
complete DNA replication (18). 2) Alternatively, pol b might be
involved in the error-prone filling of single-stranded gaps in the
daughter strand opposite the lesion. These gaps could be
formed as a part of lagging strand synthesis or as a result of
activation of alternative origins of replication in damaged chro-
mosomes after the progression of the active replication fork is
blocked by a DNA lesion (19).
Both the extent and fidelity of translesion synthesis by pol b
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could be affected by the DNA substrate (single-stranded versus
gapped). It has been shown that DNA synthesis by pol b is
distributive on DNA substrates in which primer is annealed to
a single-stranded template, while pol b conducts processive
synthesis on short gapped DNA templates with a 59-phosphate
at the end of the gap (16, 17, 20–22). With gaps of 2–6 nucle-
otides pol b exhibits increased catalytic efficiency (23–25) com-
pared with primed single-stranded DNA. However, the overall
base substitution fidelity of pol b appears to be very similar
with 2–6 nucleotide gaps and single-stranded templates
(23, 24).
The platinum complex (trans-R,R)1,2-diamminocyclohexa-
neoxalatoplatinum(II) (oxaliplatin) is currently in clinical trial
for the treatment of tumors with intrinsic and acquired resist-
ance to cisplatin. Both cisplatin and oxaliplatin form the same
types adducts on the DNA, with the most abundant being
Pt(GpG) intrastrand diadducts (26–29). However, the adducts
formed by oxaliplatin contain (trans-R,R)1,2-diamminocyclo-
hexane (dach) carrier ligands, while the adducts formed by
cisplatin contain cis-diammine carrier ligands. Previous data
from our laboratory suggest that mammalian cells are able to
replicate DNA in the presence of platinum-DNA adducts and
that the extent of replicative bypass in vivo can be influenced
by the carrier ligand of the adducts (1, 2, 4). We also have
shown recently that pol b can discriminate between cisplatin
and oxaliplatin adducts in vitro. The present study was de-
signed to evaluate whether the efficiency and carrier ligand
specificity of replicative bypass past Pt-DNA adducts by pol b
could be determined by the mode of translesion synthesis (dis-
tributive synthesis on single-stranded DNA versus processive
synthesis on gapped DNA) and whether the fidelity of replica-
tive bypass depends on the carrier ligand of the Pt-DNA ad-
ducts and/or on the DNA template structure.
EXPERIMENTAL PROCEDURES
Construction of Platinum Adduct-containing Templates—Primer-
templates were constructed from synthetic oligonucleotides as de-
scribed previously (8). Briefly, cisplatin was obtained from Sigma; Pt-
(dach)Cl2 (the biotransformation product of oxaliplatin) was provided
by Dr. S. D. Wyrick (University of North Carolina). All platination
reactions were carried out with aquated derivatives of the platinum
complexes obtained by overnight stirring in the dark at room temper-
ature of a solution containing either cisplatin or Pt(dach)Cl2 and 1.98
equivalents of silver nitrate. The final concentration of aquated deriv-
atives of the platinum complexes was 40 mM. Platination of a 12-mer
oligonucleotide containing a single GG sequence within a StuI restric-
tion site (TCTAGGCCTTCT) was performed for 2 h at 37 °C in the dark
with the 2:1 drug to oligonucleotide ratio. The oligonucleotides contain-
ing a single platinum adduct were separated from unplatinated im-
purities by electrophoresis on a 20% polyacrylamide gel. DNA was
eluted from gel slices and desalted using CENTRI-SPINTM-10 columns
(Princeton Separations, Inc).
The templates used for primer extension and steady-state kinetic
experiments are listed in Fig. 1. Site-specifically platinated 44-mer
templates were constructed as described previously (8): platinated 12-
mers were ligated with a 14-mer (left end) and an 18-mer (right end)
using a 35-mer as a scaffold. Control 44-mer templates were prepared
using unplatinated 12-mer by the same procedure. After 16-h ligation at
16 °C by T4 DNA ligase, templates were purified by MicroSpin G-25
columns (Amersham Pharmacia Biotech), restricted by StuI to ensure
the absence of any unplatinated oligonucleotides, and purified on 12%
denaturing polyacrylamide gels. Control experiments were performed
to ensure the purity of platinated templates as described previously (8).
StuI cleavage was used in all primer extension assays described below,
and only StuI-resistant elongation products were quantitated as trans-
lesion synthesis to control for any loss of platinum adducts during the
incubation. StuI cleaves .95% of undamaged templates elongated past
the StuI restriction site, but it is almost completely blocked by the
presence of either cisplatin or oxaliplatin adducts (8).
The 22-, 24-, or 25-mer primers were 59-end-labeled using T4 polynu-
cleotide kinase and [g-32P]ATP, according to the manufacturer’s proto-
col. 14- and 16-mer downstream oligonucleotides used to form 6- or
5-base-gapped templates were 59-end-phosphorylated with unlabeled
ATP. DNA substrates were prepared by annealing undamaged or pla-
tinated 44-mer templates with 32P-labeled primers alone or in combi-
nation with downstream oligonucleotides at a 1.2:1: (2) molar ratio.
Hybridization was done by heating the mixture of required oligonucleo-
tides in an annealing buffer (50 mM Tris-HCl (pH 8), 100 mM NaCl) for
10 min at 80 °C followed by slow cooling to room temperature over a
period of about 2 h. Annealing efficiencies were .95%, as evidenced by
the different mobility of the 32P-labeled primers before and after hy-
bridization to the template on nondenaturing polyacrylamide gels (data
not shown).
Primer Extension Assays—Recombinant human pol b was generously
provided by Dr. S. Wilson (NIEHS) (specific activity 1.4 units/mg). One
unit of polymerase activity is defined as the amount of enzyme required
for the incorporation of 1 nmol of dTMP in 1 min at 25 °C using
poly(dA)-p(dT)20 as a template-primer). Primer extension assays were
performed as described previously (8) using 22/44 and 24/44 primer-
templates with or without 16- or 14-mer downstream oligonucleotides
(Fig. 1, A–D). 200 fmol of primer-template (expressed as primer termini)
was incubated with pol b at 37 °C in 10-ml reactions containing 500 mM
dNTPs unless otherwise indicated. Reaction times and enzyme concen-
trations are indicated in the figures. Reactions were terminated by
heating at 80 °C for 10 min. Each reaction mixture was split into two
aliquots, one of which was incubated with StuI restriction enzyme.
Aliquots were mixed with 0.7 volume of formamide loading dye solution
containing 500 mM EDTA, 0.1% xylene cyanol, and 0.1% bromphenol
blue in 90% formamide. Before loading onto the gel, the reactions were
denatured by heating at 100 °C for 5 min and immediately transferred
to ice for 5 min. Products were resolved by denaturing polyacrylamide
gel electrophoresis (8 M urea, 16% acrylamide, 4 h at 2000 V) and then
visualized and quantified using a Molecular Dynamics PhosphorImager
and ImageQuant software. The extent of translesion synthesis on dam-
aged templates was calculated as the sum of elongation products past
the platinum adducts as a percent of total primer termini (elongated
and unelongated).
Steady-state Polymerization Kinetics—Steady-state kinetic parame-
ters Km and Vmax for dCTP incorporation were measured in standing-
start reactions as described previously (8) using the 44-mer templates
hybridized to 24- or 25-mer primers alone or in combination with
downstream 16-mer oligonucleotides (Fig. 1, B, D, E, and F). 150 fmol of
DNA substrates were replicated at 37 °C in 10-ml reaction mixtures
containing 5 fmol of pol b and variable concentrations of dCTP. Initial
time course studies indicated that under standard conditions the reac-
tion velocity is linear (i.e. conforms to steady-state kinetics) for up to 12
min for single-stranded templates and up to 6 min for gapped templates
(data not shown). Less than 20% of the primers were extended under
the steady-state conditions ensuring single hit conditions. As expected
in steady state, Vmax values were proportional to enzyme concentration
(data not shown).
The velocity of dCTP incorporation opposite the template 39-G and
59-G sites was determined using the equation y 5 (I39-G 1 I59-G)/tI21
with templates B and D (Fig. 1) for the 39-G or y 5 I59-G/tI21 with
templates E and F for the 59-G (where t is the reaction time in min;
I21, I39-G, and I59-G are the integrated gel band intensities at sites 21
(corresponding to unextended primer, 39-G, and 59-G, respectively).
The relationship between y and dCTP concentration conformed to a
Michaelis-Menten equation, as indicated by linearity in a Hanes-
Woolf plot of [dCTP]/y versus [dCTP]. Vmax (the maximum value of
reaction velocity) and Km (dCTP concentration at which the reaction
velocity is half-maximal) were determined from a Hanes-Woolf plot
by linear least squares fit. The efficiency of nucleotide insertion by
polymerase (f) was calculated as Vmax/Km. To facilitate comparison of
values for different Pt adducts, the relative insertion efficiency frel
also is reported: frel 5 fPt/fcontrol.
Misincorporation Assays—To measure nucleotide misinsertion oppo-
site Pt-GG adducts, DNA substrates shown in Fig. 1, B, D, E, and F
were used. 150 fmol of these DNA substrates were incubated with 5
fmol of pol b and 5 mM of each dNTP individually for 15 and 30 min for
control and damaged templates, respectively. Reactions were termi-
nated, and products were analyzed as described above. The kinetics of
dTTP misincorporation opposite platinated and undamaged GG sites
using templates shown in Fig. 1, C, E, and F, were determined in
reactions similar to ones described in the previous section. To detect
extension products resulting from nucleotide misincorporation, it was
necessary to increase incubation times from 1–2 to 15–30 min. The
dTTP misinsertion efficiency (fmis) was determined as the ratio of dTTP
to dCTP insertion efficiencies.
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RESULTS
In a previous study (8) we established the carrier-ligand
specificity of pol b catalyzed translesion synthesis using prim-
er-templates where the primer was placed either 2 or 53 bases
before the GG sites containing the platinum adduct. In those
studies, oxaliplatin-GG adducts were bypassed to a greater
extent than cisplatin-GG adducts, and the placement of the
primer relative to the Pt-GG adduct had no effect on the car-
rier-ligand specificity of translesion synthesis. To study the
effect of template structure on the extent and specificity of
translesion synthesis by pol b in more detail, we have per-
formed the primer extension assay using undamaged or site-
specifically platinated templates of different structure (Fig. 1,
A–D). All these DNA substrates contained the same 44-mer
template. In addition to a 22-mer primer used previously in
primer extension assays (Fig. 1A), we have utilized a 24-mer
primer (Fig. 1B) to examine the capacity of pol b to initiate
DNA synthesis from the base preceding the lesion. The same
experiments were also carried out using 6-base gapped DNA
templates with the lesion either in the center of the gap (Fig.
1C) or at the beginning of the gap (Fig. 1D).
Fig. 2, A–H, shows the time course for elongation of 22-mer
or 24-mer primers on 44-mer single-stranded and gapped
DNA templates, either undamaged or containing a single
cisplatin adduct. The positions of primers, full-length reac-
tion product (44-mer), and template sequence are indicated.
The enzyme to DNA substrate ratio was approximately 1:4 in
these experiments, which corresponds to the minimum
amount of pol b necessary to ensure measurable translesion
synthesis on all templates. As expected for such reaction
conditions, distinct bands corresponding to practically every
nucleotide in the sequence were clearly visible when undam-
aged single-stranded templates were used (Fig. 2, A and E).
Such a pattern is consistent with the distributive nature of
pol b. Singhal and Wilson (30) have shown previously that pol
b fills gaps of up to 6 nucleotides by a processive mechanism
that requires a phosphate group at the 59-end of the gap. In
agreement with these findings we observed no strong pause
sites within the 6-nucleotide gaps on undamaged DNA sub-
strates (Fig. 2, C and G). At the pol b concentrations used in
these experiments, some strand displacement was observed
with gapped DNA templates. The extent of strand displace-
ment depended on the DNA substrate utilized. For example,
with the 22/44/16 DNA template (Fig. 1C) there was a major
accumulation of products varying in length from 28 nucleo-
tides (corresponding to the end of the gap) to 32 nucleotides
(corresponding to strand displacement of four nucleotides).
This was accompanied by significant time-dependent strand
displacement to the end of the template (Fig. 2C). However,
with the 24/44/14 DNA substrate (Fig. 1D) the major stop
sites varied in length from 30 nucleotides (end of the gap) to
32 nucleotides (strand displacement of two nucleotides) (Fig.
2G). This was accompanied by limited strand displacement of
the remaining duplex DNA, which did not increase with time.
The difference in strand displacement between the 22/44/16
and 24/44/14 DNA substrates is most likely due to the sta-
bility of the duplex region immediately downstream of the
gap. For the 24/44/14 DNA substrate, the first 5 base pairs of
the duplex region downstream of the gap are all GzCs,
whereas the 22/44/16 DNA substrate contains an AzT base
pair located 2 bases downstream from the gap.
Primer extension on all damaged templates was substan-
tially reduced (Fig. 2, B, D, F, and H). When single-stranded
templates were used, the decrease in the amount of full-length
product was mainly due to a strong inhibition of dNTP incor-
poration opposite the template 39-G(Pt) (24-mer band), Fig. 2, B
and F) and 39 to the lesion (22- and 23-mer bands), Fig. 2B).
Weaker inhibition of dNTP incorporation opposite the 59-G(Pt)
(25-mer band), Fig. 2, B and F) and of chain extension from
59-G(Pt) (26-mer band), Fig. 2, B and F) was also observed.
Primer extension on damaged gapped DNA templates produced
multiple stop sites, although the relative distribution of the
products of replication was somewhat different from that seen
with single-stranded templates. Stop sites 39 from the lesion
weakened. This was most apparent for the DNA substrates
with the Pt adduct in the center of the gap (compare the 23- and
24-mer bands in gel 2D (gapped DNA) with gel 2B (single-
stranded DNA)). In addition, the stop site across from the
39-G(Pt) became more prominent and additional pause sites 1
and 2 nucleotides beyond the adduct appeared. This was most
apparent for the DNA substrates with the Pt adduct at the
beginning of the gap (compare the 27- and 28-mer bands in gel
2H (gapped DNA) and gel 2F (single-stranded DNA)). Some
strand displacement was seen with both gapped DNA tem-
plates with platinum adducts. However, in contrast to the
pattern of strand displacement for undamaged templates, less
strand displacement was seen for the 22/44/16 DNA template
(Fig. 2D) than for 24/44/14 DNA template (Fig. 2H).
The extent of translesion synthesis past the cisplatin-GG
and oxaliplatin-GG adducts was calculated as described under
FIG. 1. Primed single-stranded and gapped DNA substrate
configurations used in primer-extension and kinetic studies.
The site-specifically modified DNA templates were constructed using
combination of synthetic oligonucleotides as described under “Experi-
mental Procedures.”
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“Experimental Procedures” and is summarized in Fig. 2, I and
J (the stop sites were identical for cisplatin- and oxaliplatin-GG
adducts, so the gels for the experiment with oxaliplatin adduct
are not shown). Levels of translesion synthesis past platinum
adducts (sum of products longer than 26 nucleotides (Fig. 2, B,
D, F, and H) as a percent of total primer termini) appeared to
be similar for both the 22/44 and 24/44 single-stranded DNA
templates (Fig. 2, I and J, closed symbols). The extent of trans-
lesion synthesis past Pt-DNA adducts was increased 1.5–3-fold
with gapped DNA templates (Fig. 2, I and J, open symbols)
relative to single-stranded primed DNA templates. Further-
more, a higher extent of translesion replication was observed
for DNA templates with the Pt adduct in the center of the gap
(Fig. 2, I and J, open circles) compared with DNA templates
with the Pt adduct at the beginning of the gap (Fig. 2, I and J,
open triangles).
In agreement with our previous data on pol b-catalyzed
primer extension at low enzyme concentrations (8), cisplatin
adducts were about 2.5-fold more effective than oxaliplatin
adducts at blocking translesion synthesis on both 22/44 and
24/44 single-stranded primed templates (compare Fig. 2, I
and J, closed symbols). However, with both gapped DNA
substrates, there was relatively little difference in the extent
of translesion synthesis between templates with cisplatin-GG
and oxaliplatin-GG adducts (Fig. 2, I and J, open symbols).
We have also shown previously that when the enzyme is
present in excess to primed single-stranded DNA templates,
pol b does not appear to discriminate between cisplatin- and
oxaliplatin-DNA adducts. Thus, we examined the effect of po-
lymerase concentration on replicative bypass using the DNA
substrates described above (Fig. 3). At high enzyme concentra-
tions (2.5–25-fold excess over primer-template), pol b did not
differentiate between cisplatin and oxaliplatin adducts for any
DNA substrate tested (data not shown); therefore data are
presented for cisplatin-damaged templates only. Fig. 3 shows
the enzyme concentration-dependence and time course for
translesion synthesis past cisplatin-GG adducts using all four
DNA constructs. The extra band seen at 45 nucleotides is
characteristic of primer extension reactions with high concen-
trations of pol b and is most likely due to the intrinsic nucle-
otidyl transferase activity of pol b (8). With both 22/44 and
24/44 primed single-stranded templates at pol b to template
ratios of 25:1, strong stop sites 1 and 2 nucleotides past the
Pt-GG adducts were observed in addition to the stop sites 39 to
the Pt-GG adduct and across the lesion (Fig. 3, A and C). For
both gapped templates, the stop site immediately preceding the
Pt-GG adduct was decreased in intensity and the stop site
immediately following the Pt-GG adduct was increased in in-
tensity compared with the single-stranded templates (compare
Fig. 3, B and D, with 3, A and C). Finally, the stop sites 1 and
2 nucleotides past the Pt-GG adducts were considerably
weaker and strand displacement was significantly greater for
the template with the Pt-GG adduct at the beginning of the gap
compared with the template with the Pt-GG adduct in the
FIG. 2. Primer extension activity of
pol b using DNA substrates of differ-
ent structure. Time course experiments
were conducted using 150 fmol of undam-
aged templates (A, C, E, and G) or tem-
plates containing a single cisplatin-GG
adduct (B, D, F, and H) and 40 fmol of pol
b. Reactions with 59-32P-end-labeled
primer situated 2 bases before (A–D) or
immediately before (E–H) the Pt-GG ad-
duct were performed using primed single-
stranded (A, B, E, and F) or gapped (C, D,
G, and H) DNA substrates. Template se-
quences are shown to the left of the gels.
Platinated guanines are indicated. The
length of the primer and the position cor-
responding to the end of the gap are
shown on the right. The extent of trans-
lesion synthesis past cisplatin (I) and ox-
aliplatin (J) (gels not shown) adducts was
calculated as a percent of total primer
termini as described under “Experimen-
tal Procedures.” The primer extension re-
actions were performed using 22/44 (l)-
and 24/44 () primed single-stranded
templates and 22/44/16 (E) and 24/44/14
(ƒ) gapped DNA templates (Fig. 1). Data
are the means (6S.E.) from four different
experiments using two independent tem-
plate preparations.
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center of the gap. For example, with the DNA substrate con-
taining the Pt adduct at the beginning of the gap, no stop site
was observed at the end of the gap and strand displacement
was essentially complete (Fig. 3D). In contrast, with the DNA
substrate containing the Pt adduct in the center of the gap, a
strong stop site at the end of the gap and significantly less
strand displacement were observed (Fig. 3B).
The extent of translesion synthesis past cisplatin adducts
with high levels of pol b appeared to be identical for 22/44 and
24/44 primed single-stranded DNA substrates (Fig. 3, A and C;
Fig. 3, E and F, closed symbols). The effect of adding the 14- or
16-mer 59-phosphorylated downstream oligonucleotides to cre-
ate 6-base pair gaps (Fig. 3) was very similar to the effects
observed at lower pol b concentrations (Fig. 2). The extent of
translesion synthesis was increased with both gapped tem-
plates compared with single-stranded templates (Fig. 3, E and
F, open symbols versus closed symbols). The most significant
effect of pol b concentration was on the relative extent of
translesion synthesis with the two gapped templates. At en-
zyme to template ratios of up to 12:1, gapped DNA with the
lesion in the center of the gap was a better substrate for
translesion synthesis than gapped DNA with the lesion at the
beginning of the gap (Fig. 3E). However, at enzyme to template
ratios of greater than 12:1, the total amount of translesion
synthesis past Pt-GG sites was equal for these two DNA sub-
strates at all reaction times tested (Fig. 3F).
Steady-state Kinetics of dCTP Insertion Opposite GG Sites on
Damaged and Undamaged Templates—As shown above, oxali-
platin-GG adducts were bypassed more readily than cispla-
tin-GG adducts when the primer extension assay was per-
formed with single-stranded DNA substrates under conditions
of low enzyme concentration (Fig. 2, I and J, closed symbols)
and/or limiting dNTP concentrations (data not shown). How-
ever, during processive gap-filling synthesis, replication past
cisplatin and oxaliplatin adducts did not differ significantly
(Fig. 2, I and J, open symbols). Goodman and colleagues (31)
have shown that the steady-state kinetic assay is more sensi-
tive than the primer extension assay for determining whether
a polymerase is able to discriminate between adducts and can
provide information about the mechanism of discrimination
between adducts. This assay is performed under limiting en-
zyme concentrations and is more representative of true intra-
cellular conditions than the primer extension assay. To char-
acterize the extent of lesion bypass more quantitatively, kinetic
experiments were performed on undamaged templates and
templates with cisplatin and oxaliplatin adducts. In the previ-
ous primer-extension experiments, the strongest inhibitory ef-
fect of platinum adducts on DNA replication by pol b at low
enzyme concentrations was reduced incorporation across from
the 39- and 59-platinated guanines. Therefore, steady-state ki-
netic assays of dCTP incorporation opposite these major stop
sites were performed. Our study was done using standing start
reaction conditions where nucleotide insertion is measured at
the first template site adjacent to the original primer 39 termi-
nus. Although the absolute values of kinetic parameters, Vmax
and Km, derived from the standing start assay have limited
mechanistic significance, the ratios of Vmax/Km for damaged
versus undamaged templates are reliable measurements of the
effect of different lesions on polymerase activity (32). All exper-
iments were carried out in the presence of 30-fold excess of
template over enzyme. Prior to kinetic studies, experiments
were performed to determine the enzyme concentrations, dNTP
concentrations, and times for which product accumulation was
linear as a function of time.
The kinetic parameters for dCTP insertion opposite the tem-
plate 39- and 59-Gs using control and damaged primed single-
stranded and gapped DNA substrates (Fig. 1, B, D, E, and F)
are presented in Table I. As anticipated, the catalytic efficiency
(Vmax/Km) for dCTP incorporation opposite the 39- and 59-Gs
was enhanced substantially with 5-nucleotide and 6-nucleotide
gapped DNA compared with primed single-stranded DNA sub-
strates, mainly due to increases in Vmax. The observed 4-fold
increase in catalytic efficiency on gapped DNA relative to sin-
gle-stranded DNA is comparable with that reported previously
for 6-nucleotide gaps (24). Chagovetz et al. (24) reported that
the increase in catalytic efficiency with 6-nucleotide gapped
DNA was predominantly Km-mediated. The apparent discrep-
ancy between this report and our data may relate to differences
in the assays used to measure kinetic parameters. Chagovetz et
al. (24) used the running start kinetic assay. Since the kinetic
parameters in our experiments were determined by the stand-
ing start assay, the Vmax-governed discrimination might not
FIG. 3. Primer extension activity of pol b at high enzyme con-
centrations. Enzyme concentration dependence and time course ex-
periments were carried out using 150 fmol of DNA templates with
59-32P-end-labeled primer situated 2 bases before (A and B) and imme-
diately before (C and D) the cisplatin-GG adduct on single-stranded (A
and C) or gapped (B and D) DNA substrates. Primer extension by 0.4
nmol of pol b on control templates (first lane in each gel) were per-
formed for 15 min. Template sequences are shown to the left of the gels.
Platinated guanines are indicated. The length of the primer and the
position corresponding to the end of the gap are shown on the right. The
graphs show the enzyme concentration dependence at 15 min (E) or the
time course with 4 nmol of pol b (F) for translesion synthesis past
cisplatin adducts as a percent of total primer termini. These data were
obtained using 22/44 (l)- and 24/44 () primed single-stranded tem-
plates and 22/44/16 (E)- and 24/44/14 (ƒ) gapped DNA templates (Fig.
1). Data are means (6S.E.) from four different experiments using two
independent template preparations.
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necessarily represent the differences in the rate of polymeriza-
tion from one site to the next, but could also be due to the
differences in the rate of enzyme-DNA dissociation or associa-
tion (32).
Pt-GG adducts had little effect on the Vmax for dCTP inser-
tion opposite either the 39- or 59-Gs (Table I). On the other
hand, Pt-GG adducts increased the Km values for dCTP inser-
tion substantially (Table I). The increase in the Km values was
greater with single-stranded DNA templates (30–90-fold) than
with gapped DNA substrates (10–25-fold). Thus, the use of
gapped DNA led to a considerable increase (2–3.5-fold) in the
efficiency of nucleotide insertion across both 39-G(Pt) and 59-
G(Pt) relative to single-stranded DNA. With a single-strand
DNA template, the Km for insertion of dCTP opposite the 39-G
of an oxaliplatin-GG adduct was about one-half that for inser-
tion of dCTP opposite the 39-G of a cisplatin-DNA adduct, while
the Vmax values for both reactions were very similar (Table I).
This resulted in overall 2-fold increase in insertion efficiency
across from the 39-G of an oxaliplatin adduct. However, no
significant differences were evident between templates with
cisplatin and oxaliplatin adducts in the relative insertion effi-
ciency of dCTP opposite the 59-G(Pt) on single-stranded DNA
or opposite either the 39-G(Pt) and 59-(G)Pt on gapped DNA
(Table I).
Nucleotide Misincorporation Opposite GGs on Undamaged
and Platinated Templates—pol b is known to lack associated
proofreading activity and to exhibit high infidelity during DNA
replication in vitro (33, 34). It is reasonable to expect that the
presence of platinum adducts on DNA might influence polym-
erase fidelity and that the conformation of the adduct might be
important in determining the miscoding potential of the lesion.
Therefore, a kinetic fidelity assay to measure single nucleotide
incorporation opposite the template 39-G and 59-G was per-
formed on damaged and control single-stranded and gapped
DNA substrates. Initially, extension studies by pol b were
performed in the presence of 5 mM of either dTTP, dGTP, and
dATP to obtain qualitative information about misincorporation
across from the platinum adducts (data not shown). Primer
extension assays were performed for 15 min on control tem-
plates and for 30 min on damaged templates with a 30-fold
excess of DNA substrate over enzyme using primers which
ended just prior the template 39-G and 59-G sites. Both single-
stranded and gapped templates were utilized. Some misincor-
poration of T was detected for both control and damaged tem-
plates, except for the incorporation across from the 59-G on
single-stranded templates. However, none of the other nucleo-
tides was inserted opposite the 39-G and 59-G sites by pol b
under the conditions of these assays with any of the DNA
templates used.
A steady-state kinetic analysis of dTTP incorporation was
then performed to characterize the misincorporation efficiency
more quanitatively (Table II). Since no detectable dTTP misin-
corporation across from the 59-G on single-stranded templates
was found in the primer extension studies, kinetic experiments
were not performed with the 25/44 DNA substrate. Therefore,
the frequency of dTTP misincorporation on single-stranded
versus gapped DNA could only be compared for the 39-G. The
efficiency (Vmax/Km) of dTTP incorporation opposite the un-
damaged 39-G residue for 6-nucleotide gapped DNA substrate
was about 10 times higher compared with the single-stranded
DNA, mainly due to a decrease in apparent Km values. This
enhanced dTTP incorporation efficiency resulted in about 2.4-
fold enhanced misinsertion frequency (fmis) compared with sin-
gle-stranded DNA. The presence of a platinum lesion on the
DNA template caused a significant (15–25-fold) increase in the
misinsertion frequency opposite the 39-G site for single-
stranded substrates, but not for 6-nucleotide gapped DNA (Ta-
ble II). In addition, no significant differences in the frequency of
dTTP misincorporation opposite the 59-G(Pt) compared with an
undamaged 59-G for 5-nucleotide gapped DNA was detected.
The low frequency of T-G mispair formation with all DNA
templates was determined by both a decrease in Vmax and an
increase in Km for dTTP incorporation (Table II) compared with
dCTP incorporation (Table I) opposite a template G.
For both single-stranded and gapped DNA substrates, the
efficiency of dTTP incorporation (Vmax/Km) and frequency of
misinsertion (fmis) opposite the 39-G (Pt) were both approxi-
mately 1.7-fold higher for oxaliplatin adducts than for cisplatin
adducts (Table II). The greater efficiency of dTTP misincorpo-
ration across from the 39-G(Pt) of oxaliplatin adducts compared
with cisplatin adducts on single-stranded templates was deter-
mined by both lower Km and higher Vmax values, while for
gapped DNA substrates this difference was primarily due to an
increase in Vmax. Misincorporation opposite the 59-G of a cis-
platin adduct on the gapped substrate was too low for reliable
determination of kinetic parameters, and dTTP misincorpora-
tion opposite the 59-G(Pt) on single-stranded templates was too
low to be detected for both cisplatin and oxaliplatin adducts.
TABLE I
Steady-state kinetic analysis of dCTP insertion opposite Pt-GG adducts
Standing start kinetic assays were performed using 5 fmol of pol b and 150 fmol of primer-templates. Data were obtained using 22/44 and 24/44
primed single-stranded templates and 22/44/16 and 24/44/14 gapped DNA templates (Fig. 1). Incubation time was 1 min for control gapped DNA
substrates, 2 min for platinated gapped DNA substrates, 5 min for control primed single-stranded DNA substrates, and 10 min for platinated
primed single-stranded DNA substrates. dCTP concentrations ranged from 1 to 8 mM for the control and from 32 to 1024 mM for the platinated
templates. Kinetic parameters (Km and Vmax) and insertion efficiency (Vmax/Km) for dCTP incorporation by pol b were determined using
Hanes-Woolf plots (see “Experimental Procedures”). The relative insertion efficiency was determined as frel 5 fPt/fcontrol. Data are means (6S.E.)
from five to six different experiments using two independent template preparations. nt, nucleotide.
Target (template) Pt adduct Vmax Km Vmax/Km frel
min21 mM M21 min21
39-G (primed single-stranded DNA) Control 0.022 6 0.002 2.6 6 0.3 8300 6 470
Cisplatin 0.020 6 0.002 234 6 22 90 6 12 0.011
Oxaliplatin 0.019 6 0.001 110 6 14 181 6 25 0.022
59-G (primed single-stranded DNA) Control 0.021 6 0.002 3.2 6 0.7 6460 6 174
Cisplatin 0.014 6 0.001 95 6 8 141 6 22 0.027
Oxaliplatin 0.016 6 0.001 96 6 6 165 6 24 0.032
39-G (6-nt gap) Control 0.125 6 0.039 3.9 6 1.7 32,000 6 3000
Cisplatin 0.083 6 0.004 36.8 6 2.3 2200 6 200 0.069
Oxaliplatin 0.096 6 0.003 39.6 6 3.2 2400 6 270 0.075
59-G (5-nt gap) Control 0.090 6 0.014 3.3 6 0.7 27,000 6 6000
Cisplatin 0.092 6 0.015 77 6 6 1300 6 290 0.048
Oxaliplatin 0.100 6 0.011 80 6 7 1450 6 250 0.054
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DISCUSSION
It has been recently postulated that pol b overexpression
facilitates translesion synthesis of cisplatin adducts, leading to
increased drug tolerance and induced mutagenesis (12, 13). It
is not clear whether pol b at normal levels catalyzes sufficient
amounts of translesion synthesis to influence cisplatin cytotox-
icity, since pol b-deleted cells do not exhibit increased sensitiv-
ity to this drug treatment (17). However, mutation frequency in
response to cisplatin treatment was not measured for pol b-de-
leted cells. Therefore, the available data do not rule out the
possibility that pol b may play a role in error-prone translesion
synthesis even when expressed at normal levels.
The experiments presented here confirm the previously
reported data (5, 6, 8) showing that pol b can catalyze exten-
sive bypass of platinum-DNA adducts in a single-stranded
region of DNA. These data may be relevant to pol b’s postu-
lated participation in leading strand and most lagging strand
translesion synthesis at the replication fork. In the present
study we also found that translesion synthesis by pol b is
even greater during short gap-filling synthesis (Figs. 2 and
3), which might occur during some lagging strand translesion
synthesis (19). In agreement with the primer-extension data,
steady-state kinetic analysis also showed that the catalytic
efficiency (Vmax/Km) of translesion synthesis by pol b was
greater with gapped DNA than with single-stranded DNA
templates. Thus, when primed single-stranded DNA was
used, the efficiency of dCTP incorporation across from both
the 39- and 59-Gs of Pt-GG adducts was decreased by a factor
of 40–100 compared with incorporation across from undam-
aged guanines, while for gapped DNA only a 13–20-fold de-
crease was observed. The decrease in dCTP insertion opposite
platinated guanines resulted from a substantial increase in
the Km values for dCTP with all damaged DNA substrates
(Table I). At the same time, the Pt adducts did not appear to
affect the rate of phosphodiester bond formation, since the
apparent Vmax values were similar for all templates.
For the cisplatin-GG adduct, the efficiency (Vmax/Km) of
dCTP incorporation across from the 59-G(Pt) was two times
higher than that across from the 39-G(Pt) for primed single-
stranded substrates. These data contradict the prediction made
by Bradley et al. (35) that polymerases should have more dif-
ficulty traversing the 59-nucleotide than the 39-nucleotide. The
crystal structure of the cisplatin-GG adduct shows a greater
distortion of the 39-GzC base pair than the 59-GzC base pair (36),
while the NMR solution structure shows a greater distortion in
the vicinity of the 59-GzC base pair (37). Our data suggest that,
when bound to the active site of pol b, the cisplatin-GG adduct
may adapt a conformation which is closer to that seen in
crystals than to that seen in solution.
With the primer extension assay, primed single-stranded
DNA templates, and physiological conditions (low enzyme con-
centrations (Fig. 2, B and F) and/or low dNTP concentrations
(data not shown)), pol b catalyzes 2.5-fold more translesion
synthesis past oxaliplatin adducts than past cisplatin adducts
(Ref. 8; Fig. 2). These findings were confirmed by steady-state
kinetic experiments that showed a 2-fold higher efficiency of
dCTP incorporation opposite the 39-G of oxaliplatin-GG ad-
ducts than opposite the 39-G of cisplatin-GG adducts. This was
due almost entirely to a 2-fold decrease in the Km for dCTP
incorporation opposite the 39-G for the oxaliplatin adducts com-
pared with cisplatin adducts. In contrast, the efficiency (Vmax/
Km) of nucleotide insertion across from the 59-G(Pt) was similar
for both cisplatin- and oxaliplatin-GG adducts. Therefore, the
increased translesion synthesis past oxaliplatin adducts seen
in the primer extension experiments is determined primarily
by enhanced nucleotide incorporation across from the 39-G(Pt).
The structure of the oxaliplatin-GG adduct has not been stud-
ied in detail, but our kinetic data with pol b suggest that the
oxaliplatin- and cisplatin-GG adducts will show the greatest
conformational differences in the vicinity of the 39-G(Pt). Our
previous data show that oxaliplatin-GG adducts are bypassed
more readily than cisplatin-GG adducts by human pol g and
yeast pol z, as well as by human pol b (8). Those data suggest
that the differences in bypass of oxaliplatin-GG and cispla-
tin-GG adducts are most likely due to the conformational dif-
ferences of the adducts themselves rather than to unique in-
teractions of the adducts with the active site of an individual
DNA polymerase.
In primer extension experiments using an excess of enzyme
over single-stranded DNA, pol b did not appear to differentiate
between cisplatin and oxaliplatin adducts (Ref. 8 and Fig. 3).
Similar levels of translesion synthesis past cisplatin and oxali-
platin adducts over a wide range of enzyme concentrations
were also found with the primer extension assay during pro-
TABLE II
Steady-state kinetic analysis of dTTP insertion opposite Pt-GG adducts
Standing start kinetic assays were performed using 5 fmol of pol b and 150 fmol of primer-templates. Data were obtained using 22/44 and 24/44
primed single-stranded templates and 22/44/16 and 24/44/14 gapped DNA templates (Fig. 1). Incubation time was 15 min for control gapped and
single-stranded DNA templates and 30 min for platinated gapped and single-stranded DNA templates. dTTP concentrations ranged from 20 to
1000 mM for control and from 1000 to 10,000 mM for platinated templates. Kinetic parameters (Km and Vmax) and insertion efficiency (f 5 Vmax/Km)
for nucleotide insertion by pol b were determined using Hanes-Woolf plots (see “Experimental Procedures”). The misinsertion efficiency (fmis) was
determined as the ratio of incorrect (dTTP) to correct (dCTP) insertion efficiencies. Data are means (6S.E.) from five to six different experiments
using two independent template preparations. nt, nucleotide.
Target (template) Pt adduct Vmax Km Vmax/Km frel
min21 mM M21 min21
39-G (primed single-stranded DNA) Control 0.0027 6 0.0005 640 6 150 4.52 6 0.39 5.4 3 1024
Cisplatin 0.00058 6 0.00009 820 6 95 0.76 6 0.14 84.4 3 1024
Oxaliplatin 0.00104 6 0.00004 440 6 57 2.52 6 0.34 139.2 3 1024
59-G (primed single-stranded DNA) Control NDa ND ND ND
Cisplatin ND ND ND ND
Oxaliplatin ND ND ND ND
39-G (6-nt gap) Control 0.0020 6 0.00013 50.3 6 9.1 41.6 6 4.1 13 3 1024
Cisplatin 0.0026 6 0.0003 1700 6 200 1.5 6 0.1 6.8 3 1024
Oxaliplatin 0.0054 6 0.0013 2040 6 500 2.9 6 0.5 12.1 3 1024
59-G (5-nt gap) Control 0.0015 6 0.00008 260 6 80 7.85 6 1.83 2.9 3 1024
Cisplatin ND ND ND ND
Oxaliplatin 0.0011 6 0.00006 880 6 80 1.30 6 0.14 9 3 1024
a ND, not determined. No detectable dTTP misincorporation was observed opposite the 59-G on primed single-strand DNA. Bands produced as
a result of dTTP misincorporation across from the 59-G of the cisplatin adduct on the gapped DNA template were detectable but were too weak for
reliable measurement of kinetic parameters.
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cessive gap-filling DNA synthesis (Fig. 3). The primer exten-
sion data with gapped DNA templates were supported by
steady-state kinetic experiments which showed that pol b did
not discriminate between cisplatin and oxaliplatin adducts in
the efficiency of dCTP incorporation across from either the 39-
or the 59-G(Pt) of gapped DNA templates (Table I). The fact
that both increased enzyme concentration and the switch to a
more processive mode of action diminish the differences be-
tween oxaliplatin and cisplatin adducts suggests that the abil-
ity of pol b to discriminate between cisplatin and oxaliplatin
adducts is strongly influenced by the rate of polymerase disso-
ciation from the damaged template.
For the gapped DNA substrates, the distance of the lesion
from both the 39-primer terminus and the 59 terminus of the
downstream oligonucleotide seemed to have a considerable ef-
fect on the extent and pattern of translesion synthesis. Our
data suggest that association between pol b and gapped DNA
may be more difficult when the primer 39-end is immediately
adjacent to the lesion than when the primer is separated from
the lesion by two nucleotides. Once the polymerase successfully
associates with either of the gapped templates, replicative by-
pass proceeds processively due to binding of the 8-kDa domain
of pol b to the 59-phosphate moiety at the end of the gap (30).
This results in an increased level of replicative bypass of Pt-
DNA adducts (Figs. 2 and 3) and an increased efficiency of
nucleotide incorporation (Vmax/Km) opposite platinated gua-
nines (Table I) on gapped DNA compared with single-stranded
DNA. The position of the lesion relative to the end of the gap
also influenced the extent of strand displacement. When the Pt
adduct was located at the beginning of the gap, strand displace-
ment proceeded with the same effectiveness as with undam-
aged DNA. However, when the Pt adduct was located in the
center of the gap, completion of gap filling and subsequent
strand displacement was inhibited (Fig. 3B).
Cisplatin is known to be a mutagen in mammalian cells
(38). However, the relative mutagenicity of cisplatin and
oxaliplatin in mammalian cells has not been reported. Cis-
platin-induced mutations in human cells have been detected
at both the 59- and 39-Gs of Pt-GG adducts, and both GzC 3
TzA transversions and GzC 3 AzT transitions have been ob-
served at high frequency (39, 40). Hoffmann et al. (6) have
demonstrated that replication past cisplatin-GG adducts by
calf thymus DNA polymerase b in vitro is mutagenic. The
present study compared the fidelity of pol b during transle-
sion synthesis past cisplatin and oxaliplatin adducts on DNA
substrates of different structure. Under our experimental
conditions, dTTP was the only dNTP that was misinserted
opposite Gs to a significant degree with either undamaged
DNA or DNA containing Pt-GG adducts (data not shown).
This observation appears to conflict with previous reports
that pol b catalyzes GzT and GzA mispairs with similar effi-
ciency (24). However, previous studies have also shown that
the fidelity of pol b is highly dependent on sequence context
(23). Thus, the differences between the current and previous
studies may be related to differences in sequence context
and/or the assays used. With undamaged DNA the misincor-
poration frequency for dTTP opposite Gs was 2.4-fold greater
for gapped DNA than for single-stranded DNA (Table II). A
similar increase in misincorporation frequency for G-T mis-
pairing during 6 nucleotide gap filling synthesis was reported
by Chagovetz et al. (24). Moreover, the overall frequencies of
dTTP misinsertion opposite guanine on undamaged single-
stranded DNA and 6-nucleotide gapped DNA are in agree-
ment with previous reports (24, 41). In contrast to misincor-
poration opposite undamaged 39-G, the fidelity of dNTP
insertion opposite 39-G(Pt) was significantly (about 12-fold)
greater with gapped DNA than with single-stranded DNA
with both cisplatin- and oxaliplatin-GG adducts (Table II).
The dTTP misincorporation frequency opposite the 39-G(Pt)
with both single-stranded and gapped DNA was 1.7-fold
greater for oxaliplatin adducts than for cisplatin adducts (Ta-
ble II), which reinforces the suggestion that the conformation of
cisplatin- and oxaliplatin-GG adducts differs significantly in
the vicinity of the 39-G(Pt). However, it is important to note
that dTTP misincorportation does not appear to represent the
major mutagenic effect of platinum adducts on pol b. Hoffmann
et al. (6) have recently shown that the mutational hot spots
generated by pol b in vitro are situated 59 to the lesion and that
the frequency of frameshift mutations in that region is much
greater than the frequency of base substitution mutations.
Therefore, these data do not necessarily predict the relative
mutagenicity of cisplatin and oxaliplatin adducts in pol b over-
expressing cells.
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